Sentynl Therapeutics, a subsidiary of Zydus Lifesciences, has reached an agreement with South Korean company PRG S&T to obtain licensing rights for Progerinin (SLC-D011), an investigational drug for treating Hutchinson-Gilford Progeria Syndrome. Under the agreement, Sentynl will acquire full rights to the FDA-designated orphan drug upon achieving specified milestones, adding a second potential early-aging therapy to its rare disease product portfolio. The oral small-molecule candidate targets the harmful progeria protein and is currently undergoing Phase IIA clinical trials, with data expected before mid-2026.